A Phase 2 interventional study of Rotigotine in Restless Legs Syndrome, sponsored by UCB BIOSCIENCES, Inc.. Completed at 5 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-08-01.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 18th largest by enrollment, is one of 3 that started in 2011, is one of 6 in phase 2, and was the 11th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2011.
This study's enrollment of 14 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB BIOSCIENCES, Inc., one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2011, is one of 5 in phase 2, and was the 12th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.
Study design was changed and an amendment was prepared accordingly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Optimal dose after titration period 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)
Drug: Rotigotine
Optimal dose after titration period 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) 1 patch /day
Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study
An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: Visit 1 (Day 1) through End of Study (approximately 2 years)
Number of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study
An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: From Visit 1 (Day 1) through End of Study (approximately 2 years)
This study started to enroll subjects in USA in January 2012 and concluded in December 2015.
| Milestone | Rotigotine |
|---|---|
| Started | 14 |
| Completed | 1 |
| Not completed | 13 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Ae, non-serious non-fatal | 3 |
| Withdrew: Other | 4 |
An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| subjects | Rotigotine (Safety Set) |
|---|---|
| Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study | 3 |
An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| subjects | Rotigotine (Safety Set) |
|---|---|
| Number of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study | 10 |
Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (up to 25 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine (Safety Set) | — | 0/14 (0%) | 10/14 (71.4%) |
| Event | Rotigotine (Safety Set) |
|---|---|
| NauseaGastrointestinal disorders | 4/14 |
| VomitingGastrointestinal disorders | 3/14 |
| Upper respiratory tract infectionInfections and infestations | 3/14 |
| Urinary tract infectionInfections and infestations | 2/14 |
| PalpitationsCardiac disorders | 1/14 |
| Sinus tachycardiaCardiac disorders | 1/14 |
| Food poisoningGastrointestinal disorders | 1/14 |
| Application site pruritusGeneral disorders | 1/14 |
| Febrile disordersGeneral disorders | 1/14 |
| PyrexiaGeneral disorders | 1/14 |
All enrolled subjects who received at least 1 dose of study medication were included in the SS.
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 14 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(Years) | Rotigotine |
|---|---|
| Mean | 15.4 ± 1.2 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 10 |
| Male | 4 |
The record gives a start of Dec 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine